|
|
Blood, 1 May 2006, Vol. 107, No. 9, pp. 3564-3571.
Prepublished online as a Blood First Edition Paper on January 10, 2006; DOI 10.1182/blood-2005-07-2961.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin
Yujie Huang,
Hubing Shi,
Hao Zhou,
Xiaomin Song,
Shaopeng Yuan, and
Yongzhang Luo
From the Laboratory of Protein Chemistry, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing, China.
Nucleolin, originally described as a nuclear protein, was recently found to be expressed on the surface of endothelial cells during angiogenic. However, the functions of cell-surface nucleolin in angiogenic remain mysterious. Here we report that upon endothelial cells adhering to extracellular matrix components, vascular endothelial growth factor (VEGF) mobilizes nucleolin from nucleus to cell surface. Functional blockage or down-regulation of the expression of cell-surface nucleolin in endothelial cells significantly inhibits the migration of endothelial cells and prevents capillary-tubule formation. Moreover, nonmuscle myosin heavy chain 9 (MyH9), an actin-based motor protein, is identified as a nucleolin-binding protein. Subsequent studies reveal that MyH9 serves as a physical linker between nucleolin and cytoskeleton, thus modulating the translocation of nucleolin. Knocking down endogenous MyH9, specifically inhibiting myosin activity, or overexpressing functional deficient MyH9 disrupts the organization of cell-surface nucleolin and inhibits its angiogenic function. These studies indicate that VEGF, extracellular matrix, and intracellular motor protein MyH9 are all essential for the novel function of nucleolin in angiogenic.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Huang, N. Song, Y. Ding, S. Yuan, X. Li, H. Cai, H. Shi, and Y. Luo
Pulmonary Vascular Destabilization in the Premetastatic Phase Facilitates Lung Metastasis
Cancer Res.,
October 1, 2009;
69(19):
7529 - 7537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Song, Y. Huang, H. Shi, S. Yuan, Y. Ding, X. Song, Y. Fu, and Y. Luo
Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1{alpha}/CXCR4 Axis
Cancer Res.,
August 1, 2009;
69(15):
6057 - 6064.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Jorge, P. Navarro, P. Martinez-Acedo, E. Nunez, H. Serrano, A. Alfranca, J. M. Redondo, and J. Vazquez
Statistical Model to Analyze Quantitative Proteomics Data Obtained by 18O/16O Labeling and Linear Ion Trap Mass Spectrometry: Application to the Study of Vascular Endothelial Growth Factor-induced Angiogenesis in Endothelial Cells
Mol. Cell. Proteomics,
May 1, 2009;
8(5):
1130 - 1149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mikelis, E. Sfaelou, M. Koutsioumpa, N. Kieffer, and E. Papadimitriou
Integrin {alpha}{nu}{beta}3 is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase {beta}/{zeta}
FASEB J,
May 1, 2009;
23(5):
1459 - 1469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Pacheco-Pinedo, M. T. Budak, U. Zeiger, L. H. Jorgensen, S. Bogdanovich, H. D. Schroder, N. A. Rubinstein, and T. S. Khurana
Transcriptional and functional differences in stem cell populations isolated from extraocular and limb muscles
Physiol Genomics,
March 3, 2009;
37(1):
35 - 42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Merchant, T. D. Cummins, D. W. Wilkey, S. A. Salyer, D. W. Powell, J. B. Klein, and E. D. Lederer
Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation
Am J Physiol Renal Physiol,
October 1, 2008;
295(4):
F1254 - F1258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Stepanova, T. Lebedeva, A. Kuo, S. Yarovoi, S. Tkachuk, S. Zaitsev, K. Bdeir, I. Dumler, M. S. Marks, Y. Parfyonova, et al.
Nuclear translocation of urokinase-type plasminogen activator
Blood,
July 1, 2008;
112(1):
100 - 110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Teng, A. C. Girvan, L. K. Casson, W. M. Pierce Jr., M. Qian, S. D. Thomas, and P. J. Bates
AS1411 Alters the Localization of a Complex Containing Protein Arginine Methyltransferase 5 and Nucleolin
Cancer Res.,
November 1, 2007;
67(21):
10491 - 10500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Shi, Y. Huang, H. Zhou, X. Song, S. Yuan, Y. Fu, and Y. Luo
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Blood,
October 15, 2007;
110(8):
2899 - 2906.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Xie, I. Kobayashi, T. Kiyoshima, H. Yamaza, J.-y. Honda, K. Takahashi, N. Enoki, A. Akamine, and H. Sakai
Functional Implication of Nucleolin in the Mouse First Molar Development
J. Biol. Chem.,
August 10, 2007;
282(32):
23275 - 23283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Ireson and L. R. Kelland
Discovery and development of anticancer aptamers
Mol. Cancer Ther.,
December 1, 2006;
5(12):
2957 - 2962.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|